Skip to main content

Table 2 Laboratory findings, CSF analysis, and NCS/EMG results

From: Clinical features with anti fibroblast growth factor receptor 3 (FGFR3) antibody-related polyneuropathy: a retrospective study

Laboratory findings

FGFR3 antibody (≥3000)

14,285.71 (IQR 5000–16,750)

CSF analysis (n = 6)

WBC count

0.67 (IQR 0–1)

Protein

40.3 (IQR 38.5–41.5)

Glucose

60 (IQR 58.5–61.5)

NCS/EMG findings

Sensory axonal neuropathy

4 (28.6%)

Sensorimotor axonal neuropathy

7 (50%)

Normal result

3 (21.4%)

Type of neuropathy (using results of NCS/EMG and skin biopsy)

Non-length-dependent

6 (42.9%)

Length-dependent

8 (57.1%)

  1. Data are reported as n (%) and mean (interquartile range). CSF cerebrospinal fluid, EMG electromyography, FGFR3 fibroblast growth factor receptor 3, NCS nerve conduction studies, WBC white blood cell